Bremelanotide (PT-141)

In June 2019 the FDA approved Bremelanotide (sold under the brand name Vyleesi) as a treatment, for desire in premenopausal women diagnosed with acquired generalized hypoactive sexual desire disorder (HSDD). Its distinctive administration method and side effect profile have sparked interest in comparison, to flibanserin. While the precise way it works isn't entirely known yet bremelanotide triggers certain brain chemicals linked to arousal by attaching to receptors, in the brain that influence sexual behavior. The activation triggers the release of dopamine enhancing stimulating signals. Bremelanotide should be taken 45 minutes prior to engaging in sexual activity however the best timing, for its use is still not clearly defined. When successful, in its application it enhances levels of desire and lessens the emotional turmoil associated with sexual issues.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.